ePrints

The case for adjuvant chemotherapy in pancreatic cancer

Lookup NU author(s): Dr Deborah Stocken

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Pancreaticcancer is a difficult cancer to treat effectively. Only a small proportion of patients are suitable for resection. The long-term survival following resection alone is between 10 and 18%. Adjuvant therapy aims to improve this outcome. There have been five fully reported adjuvant trials in pancreaticcancer. The largest study is the ESPAC-1 trial which demonstrated a significant survival benefit for 5-fluorouracil chemotherapy and no survival benefit for adjuvant chemoradiotherapy. A meta-analysis of these trials has confirmed the survival benefit for chemotherapy and thus adjuvantchemotherapy is recommended as the standard of care following pancreatic resection. There are further large studies which will also help to further define the optimum adjuvantchemotherapy in these patients.

Publication metadata

Author(s): Ghaneh P, Sultana A, Shore S, Stocken DD

Publication type: Article

Publication status: Published

Journal: Best Practice and Research Clinical Gastroenterology

Year: 2006

Volume: 20

Issue: 2

Pages: 383-401

ISSN (print): 1521-6918

ISSN (electronic): 1532-1916

Publisher: Bailliere Tindall

URL: http://dx.doi.org/10.1016/j.bpg.2005.11.008

DOI: 10.1016/j.bpg.2005.11.008

Altmetrics

Share